Danilo Graticola Appointed To Bigmar Board of Directors; Industry Veteran Joins Generic Pharmaceuticals Leader.Business Editors & Health/Medical Writers JOHNSTOWN, Ohio--(BW HealthWire)--Oct. 9, 2000 Bigmar Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BGMR BGMR Bigmar Inc. (stock symbol) ), a manufacturer of generic pharmaceutical oncology products and intravenous infusion solutions, today named Danilo Graticola to the company's board of directors. A native of Milan, Italy, Graticola, 41, currently serves as president of Pharmacare S.p.A., a pharmaceutical consulting company Noun 1. consulting company - a firm of experts providing professional advice to an organization for a fee consulting firm business firm, firm, house - the members of a business organization that owns or operates one or more establishments; "he worked for a based in Milan that represents various European and Asian companies. Graticola also serves on the board of directors of Acs Dobfar, S.p.A., a leading manufacturer and marketer of antibiotics with annual sales in excess of $200 million. John G. Tramontana, chairman and chief executive officer of Bigmar, stated, "We are honored to welcome Danilo to Bigmar's board of directors. We expect to benefit from his extensive experience in state-of-the-art manufacturing, especially in the area of injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. sterile products, as we execute our strategic plans going forward." Graticola's appointment increases Bigmar's board representation to six. In addition to Graticola, the board includes: John G. Tramontana, Bigmar's chairman and chief executive officer; Cynthia R. May, a private investor and financier; Bernard Kramer, Bigmar's vice president of operations; Massimo Pedrani, managing director of Emmepi-Pharma, a pharmaceutical consulting company involved in chemical, pharmaceutical development and regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: Bigmar Inc.'s strategy is to supply world markets with a line of high-quality, affordably priced pharmaceutical products with a focus on oncology. The company has distribution rights to more than 20 generic oncological products and seven products approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , which are manufactured in the company's state-of-the-art facilities in Switzerland. Bigmar markets its products through partnerships with pharmaceutical distributors in Europe and the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and focuses on off-patent oncological drugs. For more information, visit the company's Web site, www.bgmr.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion